Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 298

1.

Challenges in the endocrine management of breast cancer.

Mouridsen HT, Rose C, Brodie AH, Smith IE.

Breast. 2003 Aug;12 Suppl 2:S2-19. Review.

PMID:
14659138
2.

Emerging role of aromatase inhibitors in the adjuvant setting.

Goss PE.

Am J Clin Oncol. 2003 Aug;26(4):S27-33. Review.

PMID:
12902874
3.
4.
5.

Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

PMID:
14535531
6.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

7.
8.

The discovery and mechanism of action of letrozole.

Bhatnagar AS.

Breast Cancer Res Treat. 2007;105 Suppl 1:7-17. Epub 2007 Oct 3. Review. Erratum in: Breast Cancer Res Treat. 2008 Nov;112(2):385.

9.

Anti-tumor effects of letrozole.

Miller WR, Anderson TJ, Dixon JM.

Cancer Invest. 2002;20 Suppl 2:15-21. Review.

PMID:
12442345
11.

Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.

Strasser-Weippl K, Badovinac-Crnjevic T, Fan L, Goss PE.

Breast. 2013 Aug;22 Suppl 2:S171-5. doi: 10.1016/j.breast.2013.07.033. Review.

PMID:
24074782
12.

The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.

Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G.

Cancer. 2004 Oct 1;101(7):1482-9. Review.

13.

Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.

Gradishar WJ.

Oncology. 2005;69(1):1-9. Epub 2005 Jul 28. Review.

PMID:
16088229
14.

Update on clinical role of tamoxifen.

Benson JR, Pitsinis V.

Curr Opin Obstet Gynecol. 2003 Feb;15(1):13-23. Review.

PMID:
12544497
15.

Aromatase inhibitors for the treatment and prevention of breast cancer.

Kalidas M, Brown P.

Clin Breast Cancer. 2005 Apr;6(1):27-37. Review.

PMID:
15899070
16.

Preliminary data from ongoing adjuvant aromatase inhibitor trials.

Goss PE.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4397s-4401s; discussion 4411s-4412s. Review.

PMID:
11916231
17.

Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.

Buzdar A.

Clin Breast Cancer. 2003 Apr;4 Suppl 1:S42-8. Review.

PMID:
12756078
18.

The role of aromatase inhibitors in early breast cancer.

Chung CT, Carlson RW.

Curr Treat Options Oncol. 2003 Apr;4(2):133-40. Review.

PMID:
12594939
19.

Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?

Howell A, Howell SJ, Clarke R, Anderson E.

J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):227-37. Review.

PMID:
11850229
20.

Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?

Freedman OC, Verma S, Clemons MJ.

Cancer Treat Rev. 2005 Feb;31(1):1-17. Epub 2004 Nov 18. Review.

PMID:
15707700

Supplemental Content

Support Center